Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
NCT00014209
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Hodgkin's disease or non-Hodgkin's lymphoma that has not responded to previous treatment.
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
04/07/2020
Locations: Tom Baker Cancer Center - Calgary, Calgary, Alberta +12 locations
Conditions: Lymphoma
Register for Updates
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00720109
Completed
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combin... Read More
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
04/04/2020
Locations: Children's Hospital of Alabama, Birmingham, Alabama +133 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Register for Updates
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
NCT00016380
Completed
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by radiation therapy. PURPOSE: This randomized phase III trial is comparing how well ondansetron works with or without dexamethasone in preventing vomiting in patients with cancer who are receiving radiation therapy to the upper abdomen.
Gender:
ALL
Ages:
Between 16 years and 120 years
Trial Updated:
04/01/2020
Locations: Cross Cancer Institute, Edmonton, Alberta +13 locations
Conditions: Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00002678
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with multiple myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients with multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/31/2020
Locations: St. Mary's/Duluth Clinic Health System, Duluth, Minnesota +36 locations
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis
NCT01318902
Completed
This study will include participants with previously treated systemic relapsed or refractory light-chain (AL) amyloidosis who require further therapy and will be aimed at determining the safety profile and the maximum tolerated dose/recommended phase 2 dose of MLN9078 (Ixazomib) administered orally.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2020
Locations: Tufts Medical Center, Boston, Massachusetts +9 locations
Conditions: Light-Chain Amyloidosis
Register for Updates
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma
NCT01023308
Completed
Panobinostat (LBH589) is a highly potent pan-deacetylase inhibitor (pan-DACi), inclusive of HDAC6, which disrupts aggresome function, promotes accumulation of cytotoxic misfolded protein aggregates and triggers myeloma cell death. Combination of pan-DAC and protease inhibition by co-treatment with panobinostat (PAN) and bortezomib (BTZ) has demonstrated synergistic cytotoxicity in vitro and in vivo in pre-clinical experiments. Furthermore, clinical experience in advanced multiple myeloma (MM) pa... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2020
Locations: Novartis Investigative Site, Phoenix, Arizona +209 locations
Conditions: Multiple Myeloma
Register for Updates
Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)
NCT00440726
Completed
This is a Phase I/II study of a drug called bortezomib given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred). Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) for treating adults with multiple myeloma which is a type of blood cancer. Bortezomib has been shown to cause cancer cells to die in studies done on animals (mice). Studies have been done that have shown that some adults and children... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/07/2020
Locations: City of Hope, Duarte, California +23 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients
NCT03348696
Completed
The REaCT TAPS clinical trial will compare a tapering dose of dexamethasone to other standards of care on the presence of taxane-associated pain syndrome (TAPS) in early stage breast cancer.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
01/06/2020
Locations: Southlake Regional Cancer Centre, Newmarket, Ontario +1 locations
Conditions: Early-stage Breast Cancer, Pain Syndrome
Register for Updates
Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
NCT02404220
Terminated
The primary objective of this study is to evaluate the safety of entospletinib in combination with vincristine (VCR), and dexamethasone (DEX) in adults with previously treated relapsed or refractory B-cell lineage acute lymphoblastic leukemia (ALL). This is a dose escalation study in which after 2 induction cycles participants may be put on maintenance for up to 36 cycles if they have obtained clinical benefit from the treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/23/2019
Locations: City of Hope, Duarte, California +12 locations
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media
NCT00956748
Withdrawn
Chronic suppurative otitis media (CSOM) can be particularly difficult to treat as a number of patients do not respond to routine antibiotic or surgical treatments. The current treatment involves administering combination antibiotic anti-inflammatory ear drops such as Ciprodex (ciprofloxacin 0.3% / dexamethasone 0.1%). Although most patients experience a relief of symptoms, a fraction of patients remain refractory to treatment. Recent findings suggest that the addition of N-acetylcysteine (0.5-2%... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/29/2019
Locations: St. Paul's Hospital BC Rotary Hearing & Balance Centre, Vancouver, British Columbia
Conditions: Otitis Media, Otorrhea
Register for Updates
Dexamethasone for Palliation - Brain Metastases
NCT00188864
Completed
Brain metastases occur when cancer cells from the initial tumour site (for example, lung or breast) spread to the brain. This develops in approximately 10% - 30% of adults with cancer. They can produce different complaints related to their effect on brain functioning, decrease in a person's ability to carry on with their usual activities, a reduction in the quality of life and shortened life expectancy. The standard treatment particularly for people with more than one brain metastasis consists... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2019
Locations: Princess Margaret Hospital, Toronto, Ontario
Conditions: Neoplasm Metastasis
Register for Updates
Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department
NCT02794441
Completed
Migraine recurrence is common amongst pediatric patients being discharged from the emergency department after treatment for migraine. Despite the commonality of migraine recurrence within the week following discharge, no known effective therapies are available in the pediatric population, though dexamethasone has been established as efficacious in the adult migraine population. The proposed study will randomly assign children and adolescents visiting the emergency department (ED) for migraine to... Read More
Gender:
ALL
Ages:
Between 8 years and 18 years
Trial Updated:
11/14/2019
Locations: Children's Hospital of Eastern Ontario, Ottawa, Ontario
Conditions: Migraine
Register for Updates